Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and Osteogenic Sarcoma

gefitinib has been researched along with Osteogenic Sarcoma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's1 (20.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Huang, Z; Lan, W; Lin, J; Shen, R; Wang, S; Wang, X; Wang, Y; Wei, H; Zhong, G1
Blank, B; Kallis, MP; Maloney, C; Soffer, SZ; Steinberg, BM; Symons, M1
Edelman, M; Kallis, MP; Lesser, M; Maloney, C; Soffer, SZ; Steinberg, BM; Symons, M; Tzanavaris, C1
Berger, W; Kubista, B; Lötsch, D; Mayr, L; Micksche, M; Pirker, C; Sevelda, F; van Schoonhoven, S; Windhager, R1
Cheshire, PJ; Daw, N; Germain, GS; Gilbertson, R; Harwood, FC; Houghton, PJ; Jenkins, JJ; Leggas, M; Panetta, JC; Peterson, J; Schuetz, JD; Stewart, CF1

Other Studies

5 other study(ies) available for gefitinib and Osteogenic Sarcoma

ArticleYear
Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.
    Acta biochimica et biophysica Sinica, 2021, Dec-08, Volume: 53, Issue:12

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclic S-Oxides; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-6; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Protein Kinase Inhibitors; STAT3 Transcription Factor; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2021
Pharmacological prevention of surgery-accelerated metastasis in an animal model of osteosarcoma.
    Journal of translational medicine, 2020, 04-30, Volume: 18, Issue:1

    Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Gefitinib; Lung Neoplasms; Mice; Neoplasm Metastasis; Osteosarcoma

2020
Gefitinib Inhibits Invasion and Metastasis of Osteosarcoma via Inhibition of Macrophage Receptor Interacting Serine-Threonine Kinase 2.
    Molecular cancer therapeutics, 2020, Volume: 19, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Proliferation; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, Nude; Neoplasm Invasiveness; Osteosarcoma; Receptor-Interacting Protein Serine-Threonine Kinase 2; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2020
EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.
    Journal of experimental & clinical cancer research : CR, 2015, Nov-02, Volume: 34

    Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Humans; Osteosarcoma; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction

2015
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
    Cancer research, 2004, Oct-15, Volume: 64, Issue:20

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Proteins; Osteosarcoma; Quinazolines; Xenograft Model Antitumor Assays

2004